{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-277571","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.361747+00:00","generated_at":"2026-05-16T21:21:45.454720+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Erasca Q3 net loss $30.6M, cash $362M; patent issued for pan-RAS drug ERAS-0015","bullets":["Net loss $30.6M ($0.11/sh) vs $31.2M in Q3 2024; R&D down to $22.5M from $27.6M.","Cash $362.4M as of Sep 30, 2025 (down from $440.5M Dec 31); runway into H2 2028.","U.S. composition of matter patent issued for ERAS-0015 covering composition through Sep 2043.","Promoted Robert Shoemaker, Ph.D., from SVP research to chief scientific officer.","Initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 expected in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-277571","json":"https://secwatch.observer/filing/0001193125-25-277571.json","markdown":"https://secwatch.observer/filing/0001193125-25-277571.md","text":"https://secwatch.observer/filing/0001193125-25-277571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000119312525277571/0001193125-25-277571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000119312525277571/eras-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:21:45.454720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}